Category: Prostate Cancer

“Lutetium-177 (¹⁷⁷Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.” Since we posted the 2017 blog below, research into Lutetium-177 has been ongoing. The opening quote for this update comes from a September, 2021 published clinical study by Sartor et al... keep reading

There is a difference between insignificant and significant prostate cancer (PCa). While opinion remains mixed regarding the need to treat insignificant PCa immediately—or whether some cases might never need treatment—agreement is virtually universal that significant PCa is not trustworthy and should thus be dealt with as soon as possible keep reading

When it comes to men’s health, you’re a responsible guy, right? You don’t overdo it on dietary fats, sugars, red meat and alcohol; you work out regularly; and you have an annual physical. And, your annual exam includes a PSA blood test if you’re over age 45 (age 40 if you have known risk factors). keep reading

Everyone with cancer worries at some level that it might come back after primary (first) treatment. There is the natural fear of the disease itself, but there’s also a mix of accompanying anxieties. A big one concerns the choice of secondary, or salvage, treatment if the primary treatment didn’t work. While these fears are more keep reading

The average male human heart is slightly less than a half percent of total body weight, and it weighs about ten times more than the same man’s prostate gland. Most people would likely agree that the heart is at least ten times more important than the prostate. However, I suspect that the average man thinks keep reading

If you know someone with a medical crystal ball who can predict a prostate cancer patient’s outcome with 100% certainty, I’d like to hire that person to help my PCa patients gain the optimum treatment plan. Until that day, I continually seek top technology advances I can use in the service of my patients. Increasingly, keep reading

Metastatic castration-resistant prostate cancer (mCRPC) is a scary diagnosis. Castration-resistant means that hormone therapy) depriving the body of male hormones) can no longer halt the cancer’s inevitable spread. Thankfully, advances in immunotherapies and other drugs do extend life, and survival for hormone-resistant patients now averages 32 months. However... keep reading

MRI-guided focused ultrasound is a new noninvasive focal treatment approach for localized low- and intermediate-risk prostate cancer. It has been in clinical study the in the U.S. for the past several years in order to evaluate its safety, effectiveness and side effect profile. The Sperling Prostate Center, along with eight other important medical centers, is keep reading

What are the odds that a man will develop prostate cancer (PCa) if he has no family history of the disease, is in otherwise good health, has not been exposed to toxic substances, and is not in a demographic group with higher PCa statistics? On average, a man has about a one chance out of keep reading

Near the end of 2015, CMS (Centers for Medicare and Medicaid Services) proposed a mea­sure that would penalize doctors who ordered PSA tests. It would be an economic penalty, in some form of a fine. Aside from being a harsh measure, it would reinforce a trend already noted in published studies: since the US Preventive ...

keep reading